These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 30594749)
1. The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma. Youssef G; Gillett C; Rampling D; Chagtai T; Virasami A; Barton J; Edwards D; Sebire N; Anderson J; Montano X Hum Pathol; 2019 Apr; 86():182-192. PubMed ID: 30594749 [TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: a potential novel prognostic marker for breast cancer. Youssef G; Gillett C; Agbaje O; Crompton T; Montano X Mod Pathol; 2014 Mar; 27(3):361-74. PubMed ID: 23948750 [TBL] [Abstract][Full Text] [Related]
3. A Potential Prognostic Gene Signature Associated with p53-Dependent NTRK1 Activation and Increased Survival of Neuroblastoma Patients. Currie D; Wong N; Zane I; Rix T; Vardakastanis M; Claxton A; Ong KKV; Macmorland W; Poivet A; Brooks A; Niola P; Huntley D; Montano X Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398114 [TBL] [Abstract][Full Text] [Related]
4. Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation. Montano X Oncogene; 2009 Oct; 28(43):3787-800. PubMed ID: 19749791 [TBL] [Abstract][Full Text] [Related]
5. Analysis of SARS-CoV-2 infection associated cell entry proteins ACE2, CD147, PPIA, and PPIB in datasets from non SARS-CoV-2 infected neuroblastoma patients, as potential prognostic and infection biomarkers in neuroblastoma. Bergsneider B; Bailey E; Ahmed Y; Gogineni N; Huntley D; Montano X Biochem Biophys Rep; 2021 Sep; 27():101081. PubMed ID: 34307909 [TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma. de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590 [TBL] [Abstract][Full Text] [Related]
12. Aberrant promoter 2 methylation‑mediated downregulation of protein tyrosine phosphatase, non‑receptor type 6, is associated with progression of esophageal squamous cell carcinoma. Liu L; Zhang S; Liu X; Liu J Mol Med Rep; 2019 Apr; 19(4):3273-3282. PubMed ID: 30816454 [TBL] [Abstract][Full Text] [Related]
13. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma. Fukahori S; Yano H; Tsuneoka M; Tanaka Y; Yagi M; Kuwano M; Tajiri T; Taguchi T; Tsuneyoshi M; Kojiro M J Pediatr Surg; 2007 Nov; 42(11):1831-40. PubMed ID: 18022432 [TBL] [Abstract][Full Text] [Related]
15. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322 [TBL] [Abstract][Full Text] [Related]
16. Expression of P27(KIP1) is prognostic and independent of MYCN amplification in human neuroblastoma. Bergmann E; Wanzel M; Weber A; Shin I; Christiansen H; Eilers M Int J Cancer; 2001 May; 95(3):176-83. PubMed ID: 11307151 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of promoter DNA methylation in patients with childhood neuroblastoma. Lau DT; Hesson LB; Norris MD; Marshall GM; Haber M; Ashton LJ Clin Cancer Res; 2012 Oct; 18(20):5690-700. PubMed ID: 22929802 [TBL] [Abstract][Full Text] [Related]
18. The von Hippel-Lindau tumor suppressor gene expression level has prognostic value in neuroblastoma. Hoebeeck J; Vandesompele J; Nilsson H; De Preter K; Van Roy N; De Smet E; Yigit N; De Paepe A; Laureys G; Påhlman S; Speleman F Int J Cancer; 2006 Aug; 119(3):624-9. PubMed ID: 16506218 [TBL] [Abstract][Full Text] [Related]
19. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206 [TBL] [Abstract][Full Text] [Related]
20. The influence of biologic factors on the surgical decision in advanced neuroblastoma. Hsu WM; Jen YM; Lee H; Kuo ML; Tsao PN; Chen CN; Lai DM; Lin MT; Lai HS; Chen WJ; Hsieh FJ Ann Surg Oncol; 2006 Feb; 13(2):238-44. PubMed ID: 16418884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]